UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Keratins in health and cancer: more than mere epithelial cell markers

Oncogene, 2011-01, Vol.30 (2), p.127-138

Karantza, V

2011

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.397-404

2019

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.405-411

2019

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Annals of oncology, 2020-05, Vol.31 (5), p.569-581

2020

Volltextzugriff (PDF)

Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways

Oncogene, 2015-06, Vol.34 (23), p.2968-2977

2015

Volltextzugriff (PDF)

KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)

Annals of oncology, 2019-05, Vol.30, p.iii38-iii38

2019

Volltextzugriff (PDF)

Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial

Annals of oncology, 2019-05, Vol.30, p.iii2-iii2

2019

Volltextzugriff (PDF)

The Pak4 protein kinase is required for oncogenic transformation of MDA-MB-231 breast cancer cells

Oncogenesis (New York, NY), 2013-06, Vol.2 (6), p.e50-e50

2013

Volltextzugriff (PDF)

P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

Breast (Edinburgh), 2023-04, Vol.68, p.S63-S64

2023

Volltextzugriff (PDF)

The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis

Oncogene, 2010-11, Vol.29 (44), p.5883-5894

2010

Volltextzugriff (PDF)

Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

European journal of cancer (1990), 2017-02, Vol.72, p.S16-S16

2017

Volltextzugriff (PDF)

Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy

Annals of oncology, 2019-05, Vol.30, p.iii34-iii35

2019

Volltextzugriff (PDF)

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Annals of oncology, 2019-10, Vol.30, p.v853-v854

2019

Volltextzugriff (PDF)

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)

Annals of oncology, 2018-10, Vol.29, p.viii31-viii31

2018

Volltextzugriff (PDF)

Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

Annals of oncology, 2017-09, Vol.28, p.v608-v608

2017

Volltextzugriff (PDF)

Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study

European journal of cancer (1990), 2017-02, Vol.72, p.S38-S38

2017

Volltextzugriff (PDF)

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567

2022

Volltextzugriff (PDF)

Significance of Phospho(Ser73)-K8 Expression in Women With Breast Cancer of Triple Negative Phenotype

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S69-S70

2014

Volltextzugriff (PDF)

Autophagy Inhibition by Chloroquine Radiosensitizes Colorectal Cancer Cells to Radiation Therapy

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S692-S692

2012

Volltextzugriff (PDF)

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

The lancet oncology, 2019-03, Vol.20 (3), p.371-382

2019

Volltextzugriff (PDF)

121TiPKEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

4ORelationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

186P Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy

Annals of oncology, 2022-09, Vol.33, p.S621

2022

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Englisch
(95)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(12)
Medicin Och Hälsovetenskap
(12)
Animals
(10)
Female
(9)
Biochemistry & Molecular Biology
(8)
Oncology
(8)
Adult
(7)
Breast Cancer
(7)
Apoptosis
(6)
Cell Biology
(6)
Middle Aged
(6)
Pembrolizumab
(6)
Tumors
(6)
Immunotherapy
(5)
Mice
(5)
Triple Negative Breast Neoplasms - Drug Therapy
(5)
Aged
(4)
Antibodies, Monoclonal, Humanized - Adverse Effects
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Keratins in health and cancer: more than mere epithelial cell markers

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways

KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)

Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial

The Pak4 protein kinase is required for oncogenic transformation of MDA-MB-231 breast cancer cells

P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis

Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Pembrolizumab for Early Triple-Negative Breast Cancer

A novel framework for evaluating biomarker response relationships in immuno-oncology (IO)

Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Significance of Phospho(Ser73)-K8 Expression in Women With Breast Cancer of Triple Negative Phenotype

Autophagy Inhibition by Chloroquine Radiosensitizes Colorectal Cancer Cells to Radiation Therapy

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

121TiPKEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)

4ORelationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial

186P Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy

Suchergebnisse filtern